🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Nociplastic Pain in Patients Diagnosed With Subacromial Pain Syndrome (SAPS)

Recruitingn/aAges 18 Years - 70 YearsAllVejle Hospital
NCT07792434 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this cross-sectional study is to estimate the prevalence of the nociplastic pain phenotype, according to the IASP clinical criteria, among patients diagnosed with SubAcromial Pain Syndrome (SAPS). The main question it aims to answer is: What is the prevalence of the nociplastic pain phenotype in patients diagnosed with SAPS in an outpatient clinic? Primary outcome: Proportion of patients with SAPS meeting the IASP criteria for nociplastic pain.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Diagnosed with SAPS (dm751, dm753, dm754, dm755 2. Shoulder pain ≥ 3 months 3. ≥ 3 out of 5 specific shoulder tests 4. Age 18-70 years 5. Increased pain during active arm elevation 6. Pain during active elevation ≥ 3 (VAS) Exclusion Criteria: 1. Severe visual impairment 2. Epilepsy 3. Severe cognitive or physical impairment 4. Language barrier (Danish)
💊

What it tests

  • Clinical evaluation
📍

Where

1 site
Vejle Hospital
Vejle, Denmark
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy